Margin index: A new method for prediction of residual disease after breast-conserving surgery

Julie A. Margenthaler, Feng Gao, Vicki Klimberg

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: We hypothesized that the optimum margin after breast-conserving therapy (BCT) should depend on the original size of the tumor. We propose that "margin index"-a relationship of the margin obtained to the size of the tumor-is a better predictor of residual disease on reexcision than margin alone. Methods: We identified 475 consecutive patients with Stage I-II breast cancer, with or without ductal carcinoma in situ, who were treated with BCT from 1998-2008 who also underwent reexcision for close margins. Margin index was calculated as follows: margin index = closest margin (mm)/tumor size (mm) × 100. A receiver operating curve was created using the derived margin index and the presence or absence of residual disease in the reexcision specimen. Sensitivity and specificity were calculated at various margin indices to determine the optimum margin index. Results: Of the 475 patients, 102 (21%) had residual disease in the reexcision specimen. The optimum margin index was >5; the risk of residual disease for a margin index >5 was only 3.2%. The sensitivity and specificity of a margin index cutoff of 5 was 85 and 73%, respectively. The overall c index for the receiver operating curve was 0.88. The margin index was the only factor predictive of residual disease in multivariate analysis. Conclusions: Margin index is a reliable method for the prediction of residual disease after attempted BCT with close margins. This simple calculation may be helpful for identifying patients who require reexcision before radiation therapy and those who may be able to forego additional surgical interventions.

Original languageEnglish (US)
Pages (from-to)2696-2701
Number of pages6
JournalAnnals of Surgical Oncology
Volume17
Issue number10
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Segmental Mastectomy
Breast
Sensitivity and Specificity
Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Radiotherapy
Therapeutics
Multivariate Analysis
Breast Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Margin index : A new method for prediction of residual disease after breast-conserving surgery. / Margenthaler, Julie A.; Gao, Feng; Klimberg, Vicki.

In: Annals of Surgical Oncology, Vol. 17, No. 10, 10.2010, p. 2696-2701.

Research output: Contribution to journalArticle

@article{a54bff9c51f3483584f1873f466ae096,
title = "Margin index: A new method for prediction of residual disease after breast-conserving surgery",
abstract = "Background: We hypothesized that the optimum margin after breast-conserving therapy (BCT) should depend on the original size of the tumor. We propose that {"}margin index{"}-a relationship of the margin obtained to the size of the tumor-is a better predictor of residual disease on reexcision than margin alone. Methods: We identified 475 consecutive patients with Stage I-II breast cancer, with or without ductal carcinoma in situ, who were treated with BCT from 1998-2008 who also underwent reexcision for close margins. Margin index was calculated as follows: margin index = closest margin (mm)/tumor size (mm) × 100. A receiver operating curve was created using the derived margin index and the presence or absence of residual disease in the reexcision specimen. Sensitivity and specificity were calculated at various margin indices to determine the optimum margin index. Results: Of the 475 patients, 102 (21{\%}) had residual disease in the reexcision specimen. The optimum margin index was >5; the risk of residual disease for a margin index >5 was only 3.2{\%}. The sensitivity and specificity of a margin index cutoff of 5 was 85 and 73{\%}, respectively. The overall c index for the receiver operating curve was 0.88. The margin index was the only factor predictive of residual disease in multivariate analysis. Conclusions: Margin index is a reliable method for the prediction of residual disease after attempted BCT with close margins. This simple calculation may be helpful for identifying patients who require reexcision before radiation therapy and those who may be able to forego additional surgical interventions.",
author = "Margenthaler, {Julie A.} and Feng Gao and Vicki Klimberg",
year = "2010",
month = "10",
doi = "10.1245/s10434-010-1079-z",
language = "English (US)",
volume = "17",
pages = "2696--2701",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Margin index

T2 - A new method for prediction of residual disease after breast-conserving surgery

AU - Margenthaler, Julie A.

AU - Gao, Feng

AU - Klimberg, Vicki

PY - 2010/10

Y1 - 2010/10

N2 - Background: We hypothesized that the optimum margin after breast-conserving therapy (BCT) should depend on the original size of the tumor. We propose that "margin index"-a relationship of the margin obtained to the size of the tumor-is a better predictor of residual disease on reexcision than margin alone. Methods: We identified 475 consecutive patients with Stage I-II breast cancer, with or without ductal carcinoma in situ, who were treated with BCT from 1998-2008 who also underwent reexcision for close margins. Margin index was calculated as follows: margin index = closest margin (mm)/tumor size (mm) × 100. A receiver operating curve was created using the derived margin index and the presence or absence of residual disease in the reexcision specimen. Sensitivity and specificity were calculated at various margin indices to determine the optimum margin index. Results: Of the 475 patients, 102 (21%) had residual disease in the reexcision specimen. The optimum margin index was >5; the risk of residual disease for a margin index >5 was only 3.2%. The sensitivity and specificity of a margin index cutoff of 5 was 85 and 73%, respectively. The overall c index for the receiver operating curve was 0.88. The margin index was the only factor predictive of residual disease in multivariate analysis. Conclusions: Margin index is a reliable method for the prediction of residual disease after attempted BCT with close margins. This simple calculation may be helpful for identifying patients who require reexcision before radiation therapy and those who may be able to forego additional surgical interventions.

AB - Background: We hypothesized that the optimum margin after breast-conserving therapy (BCT) should depend on the original size of the tumor. We propose that "margin index"-a relationship of the margin obtained to the size of the tumor-is a better predictor of residual disease on reexcision than margin alone. Methods: We identified 475 consecutive patients with Stage I-II breast cancer, with or without ductal carcinoma in situ, who were treated with BCT from 1998-2008 who also underwent reexcision for close margins. Margin index was calculated as follows: margin index = closest margin (mm)/tumor size (mm) × 100. A receiver operating curve was created using the derived margin index and the presence or absence of residual disease in the reexcision specimen. Sensitivity and specificity were calculated at various margin indices to determine the optimum margin index. Results: Of the 475 patients, 102 (21%) had residual disease in the reexcision specimen. The optimum margin index was >5; the risk of residual disease for a margin index >5 was only 3.2%. The sensitivity and specificity of a margin index cutoff of 5 was 85 and 73%, respectively. The overall c index for the receiver operating curve was 0.88. The margin index was the only factor predictive of residual disease in multivariate analysis. Conclusions: Margin index is a reliable method for the prediction of residual disease after attempted BCT with close margins. This simple calculation may be helpful for identifying patients who require reexcision before radiation therapy and those who may be able to forego additional surgical interventions.

UR - http://www.scopus.com/inward/record.url?scp=78049475247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049475247&partnerID=8YFLogxK

U2 - 10.1245/s10434-010-1079-z

DO - 10.1245/s10434-010-1079-z

M3 - Article

C2 - 20422459

AN - SCOPUS:78049475247

VL - 17

SP - 2696

EP - 2701

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -